Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
11 2021
Historique:
received: 13 03 2021
revised: 02 07 2021
accepted: 09 07 2021
pubmed: 23 7 2021
medline: 30 11 2021
entrez: 22 7 2021
Statut: ppublish

Résumé

The clinical implications of deletions within chromosome 14q32 in CLL pathogenesis remain unclear. We examined the frequency of 14q32 deletions among CLL cases by karyotype and FISH, categorized the variation using genomic microarray, and assessed the prognostic impact by time-to-first-treatment (TTFT) analysis. A 14q32 abnormality was detected in 35 % (245/698) of cases, with the majority containing a 5' partial telomeric 14q32 deletion. These deletions within the IGH variable region (35/40) ranged from 236 kb to 1.4 Mb involving FAM30A, ADAM6, LINC00226, and LINC00221. The 214 kb minimum deleted region implicated in CLL pathogenesis encompassed LINC00221. Cases with a 14q32 deletion had a shorter median TTFT compared to cases with a sole deletion/nullisomy 13q, a good prognostic indicator, and longer than cases with a sole deletion of 11q or 17p, conferring an unfavorable prognosis. This investigation underscores the importance of comprehensive testing to apprehend the implications of 14q32 deletions in CLL.

Identifiants

pubmed: 34293710
pii: S0145-2126(21)00166-1
doi: 10.1016/j.leukres.2021.106665
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106665

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Rachel A Harris (RA)

Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE, United States.

Jadd M Stevens (JM)

Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE, United States.

Diane L Pickering (DL)

Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE, United States.

Pamela A Althof (PA)

Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE, United States.

Lynette M Smith (LM)

Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, United States.

Jennifer N Sanmann (JN)

Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE, United States.

Bhavana J Dave (BJ)

Human Genetics Laboratory, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address: bdave@unmc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH